tbuckley/cabot-search huggingface dataset:
Abstract MP165: Exosome-mediated Encapsulation Alters AAV Antigenicity and Infectivity: Implications for Gene Delivery in the Heart
Authors: Marta Adamiak, Yaxuan Liang, Cherrie Sherman, Shweta Lodha, Erik Kohlbrenner, Dongtak Jeong, Delaine K Ceholski, Navneet Dogra, Nicole Dubois, Roger J Hajjar, Susmita SAHOO
Journal: Circulation Research (2020)

Gene therapy is a promising approach for the treatment of cardiovascular disease. Current strategies for myocardial gene transfer include the use of adeno-associated virus (AAV) vectors. However, AAVs may not be ideal for gene therapy vectors owing to pre-existing AAV capsid immunity in the human population that may reduce transduction efficacy and hinder preclinical-to-clinical translation. Interestingly, recent studies suggest that exosome-mediated encapsulation may protect viruses from neutralizing antibodies (NAbs) against the capsid and promote viral infectivity. Here, we describe the ability of exosome-enveloped AAVs, i.e. exosomal AAVs (eAAVs), to evade NAbs and serve as a highly efficient gene delivery tool for cardiovascular therapeutics. We have developed a method to purifiy eAAVs from AAV-producing HEK-293T cells, and used electron/confocal microscopy, qPCR, immunoblotting, dynamic light scattering and interferometric imaging measurements to characterize eAAV morphology, contents and mechanism of action. We confirmed eAAVs represent vesicular fractions that exhibit common exosome phenotype, along with the presence of virus particles, and demonstrated that eAAV infectious entry potentially involves trafficking via endocytic compartments. Using flow cytometry, Langendorff perfusion system and bioluminescence imaging, we then evaluated efficiency of heart targeting for eAAV9/eAAV6 and standard AAV9/AAV6 encoding for mCherry or firefly luciferase in human cardiomyocytes in vitro and in mouse model in vivo . Regardless of the presence or absence of NAbs, we showed that eAAVs are more efficient in transduction in the same titer ranges as compared to standard AAVs. To test therapeutic efficacy, we intramyocardially injected eAAV9 or AAV9 vectors encoding for SERCA2a in NAb+ post-myocardial infarction mice and further evaluated cardiac function using echocardiography. Remarkably, eAAV9-SERCA2a outperformed standard AAVs significantly improving cardiac function in the presence of NAbs (%EF 55.14 ± 3.50 compared to 27.31 ± 1.63 at 6 weeks, respectively). In summary, delivery of AAVs protected by carrier exosomes (i.e. eAAVs) may retain the clinical benefits of AAVs while addressing one of its major challenges.
Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile
Authors: Sophie A. Herbst, Mattias Vesterlund, Rozbeh Jafari, Ioannis Siavelis, Matthias Stahl, Eva Schitter, Alexander J. Helmboldt, Murat Iskar, Nora Liebers, Felix Czernilofsky, Tobias Roider, Peter-Martin Bruch, Junyan Lu, Sarah Richter, Georgios Mermelekas, Husen Muhammad Umer, Mareike Knoll, Carolin Kolb, Angela Lenze, Xiaofang Cao, Cecilia Österholm-Corbascio, Sebastian Scheinost, Matthias Ganzinger, Larry Mansouri, Katharina Kriegsmann, Mark Kriegsmann, Carsten Mueller-Tidow, Peter Dreger, Simon Anders, Marc Zapatka, Marco Herling, Richard Rosenquist, Stephan Stilgenbauer, Thorsten Zenz, Wolfgang Huber, Eugen Tausch, Janne Lehtiö, Sascha Dietrich
Journal: Blood (2020)
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Authors: David J. Vanness, James Lomas, Hannah Ahn
Journal: Annals of Internal Medicine (2020)

Background: Cost-effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus exists about what threshold for the incremental cost-effectiveness ratio (ICER) in dollars per quality-adjusted life-year (QALY) gained indicates whether treatments are likely to be cost-effective in the United States. Objective: To estimate a U.S. cost-effectiveness threshold based on health opportunity costs. Design: Simulation of short-term mortality and morbidity attributable to persons dropping health insurance due to increased health care expenditures passed though as premium increases. Model inputs came from demographic data and the literature; 95% uncertainty intervals (UIs) were constructed. Setting: Population-based. Participants: Simulated cohort of 100 000 individuals from the U.S. population with direct-purchase private health insurance. Measurements: Number of persons dropping insurance coverage, number of additional deaths, and QALYs lost from increased mortality and morbidity, all per increase of $10 000 000 (2019 U.S. dollars) in population treatment cost. Results: Per $10 000 000 increase in health care expenditures, 1860 persons (95% UI, 1080 to 2840 persons) were simulated to become uninsured, causing 5 deaths (UI, 3 to 11 deaths), 81 QALYs (UI, 40 to 170 QALYs) lost due to death, and 15 QALYs (UI, 6 to 32 QALYs) lost due to illness; this implies a cost-effectiveness threshold of $104 000 per QALY (UI, $51 000 to $209 000 per QALY) in 2019 U.S. dollars. Given available evidence, there is about 14% probability that the threshold exceeds $150 000 per QALY and about 48% probability that it lies below $100 000 per QALY. Limitations: Estimates were sensitive to inputs, most notably the effects of losing insurance on mortality and of premium increases on becoming uninsured. Health opportunity costs may vary by population. Nonhealth opportunity costs were excluded. Conclusion: Given current evidence, treatments with ICERs above the range $100 000 to $150 000 per QALY are unlikely to be cost-effective in the United States. Primary Funding Source: None.
OC-072 Differences in therapy approaches and outcomes in paediatric and adult onset crohn’s disease with perianal fistula: comparison of 2 ecco collaborative multicentre fistula cohorts
Authors: C Tzivinikos, M Nair, K Ashton, T Drskova, K Sahnan, R Muhammed, D Devadason, O Hradsky, K Crook, R Palmer, A Akbar, M Thomson, A Hart, G Fiorino, C Black, D Pugliese, A Armuzzi, K Katsanos, D Christodoulou, G Maconi, C Selinger, U Kopylov, M Bosca-Watts, K Karmiris, PEllul P, S Ben-Horin, S Danese, S Sebastian
Journal: Gut (2017)

Introduction  There is no comparative data on outcomes in perianal fistulas in paediatric/adolescent versus adult onset CD. Management paradigms in perianal fistulas in Crohn’s disease is not fully defined and approaches from paediatric and adult IBD clinicians and surgeons may be different. We aimed to study any differences in diagnostic and treatment approaches and outcomes in paediatric/adolescent onset CD with perianal fistula (CD-PAF) and adult onset disease.  Method  Data was collected on patients included in 2 retrospective multicentre multinational cohorts (11 adult and 7 paediatric centres) of perianal fistula with paediatric/adolescent onset and adult onset CD PAF. We evaluated fistula characteristics, surgical and medical treatments following onset of CD-PAF and fistula healing. We also compared re-intervention rates:the need for re-insertion of seton or abscess drainage or diverting stoma or proctectomy.  Results  253 adults and 116 paediatric/adolescent patients were included. Complex fistulas were identified in 53% of adult and 67% of paediatric/adolescent group. Proctitis was recorded in 43% of adult onset and in 3% of paediatric/adolescent onset CD-PAF. Significantly higher proportion of adult CD-PAF patients had seton insertion (15% vs 54%, p  Conclusion  Paediatric/adolescent onset CD-PAF appears to have better outcomes with less radical surgery or re-interventions when compared to adult onset disease despite less frequent use of seton.  Disclosure of Interest  None Declared
ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
Authors: Claire Roddie, Maeve A O'Reilly, Maria A V Marzolini, Leigh Wood, Juliana Dias, Amaia Cadinanos Garai, Leticia Bosshard, Mahnaz Abbasian, Mark W. Lowdell, Graham Wheeler, Joanna Olejnik, Bilyana Popova, Laura Clifton-Hadley, Yashma Pathak, Victoria Spanswick, Helen Lowe, John A. Hartley, Farhatullah Syed, Waseem Qasim, Farzin Farzaneh, David C. Linch, Martin Pule, Karl S Peggs
Journal: Blood (2020)
Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
Authors: Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim V Ptushkin, Ana Marin Niebla, Ramon Garcia-Sanz, Andrey Zaritskey, Steven Le Gouill, Christian Buske, Marlies Van Hoef, Thomas Perretti, Monique S Tomiczek, Anastasios Stathis
Journal: Blood (2020)
Prevalence of Gaucher Disease in Patients of Unknown Cause of Splenomegaly and/or Thrombocytopenia in Saudi Arabia
Authors: Marwan Elbagoury, Abdulelah Ismail Qadi, Ayman Hejazi, Fahad Alabbas, Ghaleb El Yamany, Hussain H. Al Saeed, Ohoud F. Kashari
Journal: Blood (2020)
Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant
Authors: Karen Sweiss, Eric Wenzler, Hung H Nguyen, Avadhut D Joshi, Rosa Yeh, Gregory Sampang Calip, Jeremy Johnson, Donald Irby, Mitch A. Phelps, Damiano Rondelli, Pritesh Patel
Journal: Blood (2020)
Prevalence of parental mental illness and association with socioeconomic adversity among children in Sweden between 2006 and 2016: a population-based cohort study
Authors: Matthias Pierce, Kathryn M Abel, Joseph Muwonge, Susanne Wicks, Alicia Nevriana, Holly Hope, Christina Dalman, Kyriaki Kosidou
Journal: The Lancet Public Health (2020)

Children of parents with mental illness are a vulnerable group, but their numbers and their exposure to adversity have rarely been examined. We examined the prevalence of children with parents with mental illness in Sweden, trends in prevalence from 2006 to 2016, and these children's exposure to socioeconomic adversity.We did a population-based cohort study among all children (aged <18 years) born in Sweden between Jan 1, 1991, and Dec 31, 2011, and their parents, followed up between Jan 1, 2006, and Dec 31, 2016. We included children who were identified in the Total Population Register and linked to their birth parents, excluding adopted children and those with missing information on both birth parents. We used a comprehensive register linkage, Psychiatry Sweden, to follow up for indicators of parental mental illness and socioeconomic adversity. Marginal predictions from a standard logistic regression model were used to estimate age-specific, 3-year period prevalence of parental mental illness and trends in prevalence for 2006-16. Using cross-sectional data on each child, indicators of socioeconomic adversity were compared between children with and without concurrent parental mental illness using logistic regression.Of 2 198 289 children born in Sweden between Jan 1, 1991, and Dec 31, 2011, we analysed 2 110 988 children (96·03% of the total population). The overall prevalence of children with diagnosed parental mental illness between 2006 and 2016 was 9·53% (95% CI 9·50-9·57). This prevalence increased with age of the child, from 6·72% (6·65-6·78) of the youngest children (0 to <3 years) to 10·80% (10·73-10·89) in the oldest (15 to <18 years). The prevalence of diagnosed parental mental illness increased from 8·62% (8·54-8·69) in 2006-09 up to 10·95% (10·86-11·03) in 2013-16. Children with any type of parental mental illness had markedly higher risk of socioeconomic adversity, such as living in poorer households or living separately from their parents.Currently, 11% of all Swedish children have a parent with a mental illness treated within secondary care. These children have markedly higher risk of broad socioeconomic adversity than do other children. There is a need to understand how socioeconomic adversity and parental mental illness influence vulnerability to poor life outcomes in these children.European Research Council, National Institute for Health Research, Region Stockholm, and the Swedish Research Council.
MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
Authors: Patrick Mellors, Surendra Dasari, Mindy Kohlhagen, Bonnie Kaye Arendt, Morie A. Gertz, Shaji K. Kumar, Francis K. Buadi, Maria Alice V. Willrich, John A. Lust, Prashant Kapoor, Martha Q. Lacy, David Dingli, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Suzanne R. Hayman, Taxiarchis Kourelis, Rahma M Warsame, Eli Muchtar, Nelson Leung, Ronald S. Go, Yi Lin, Wilson I Gonsalves, Mustaqeem Siddiqui, Robert A. Kyle, S. Vincent Rajkumar, David L. Murray, Angela Dispenzieri
Journal: Blood (2020)
Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine
Authors: Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. Dinardo, Jan Novak, Vlatko Pejsa, Don A. Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H Wei, Cat Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Journal: Blood (2020)
Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms
Authors: Hussein A Abbas, Feng Wang, Yue Wei, Hui Yang, Guillermo Montalban Bravo, Rashmi Kanagal-Shamanna, Caleb Class, Faezeh Darbaniyan, Jianhua Zhang, Andy Futreal, Guillermo Garcia-Manero
Journal: Blood (2020)
DNA Variants Involved in Regulation of Fetal Hemoglobin in Mexican Patients with Sickle Cell Disease. a Preliminary Analysis
Authors: Lourdes Del Carmen Rizo-De La Torre, Francisco Javier Perea-Díaz, Efrain Aquino, Martha Venegas, Carmela Hernández-Carbajal, Laura Lucía Espinoza-Mata, Bertha Ibarra-Cortés
Journal: Blood (2020)
Factors Affecting Post-Transplant Relapse of Acute Lymphoblastic Leukemia (ALL) in Children According on the Intensity of Conditioning
Authors: Elena Vladimirovna Semenova, Polina Valerievna Kozhokar, Olesia V Paina, Zhemal Zarifovna Rakhmanova, Anastasia S Frolova, Luibov Tsvetkova, Kirill Alexandrovich Ekushov, Tatiana A Bykova, Anna A. Osipova, Inna Markova, Sergey N. Bondarenko, Boris I Smirnov, Ildar M Barkhatov, Tatyana L. Gindina, Ivan S. Moiseev, Axel R. Zander, Ludmila S Zubarovskaya
Journal: Blood (2020)
Exploring <i>POU2AF1 (</i>BOB-1<i>) D</i>ependency and Transcription Addiction in Multiple Myeloma
Authors: Zuzana Chyra, Mehmet Kemal Samur, Anil Aktas-Samur, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Masood A. Shammas, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2020)
Putative Germline Variants in the Predisposition Genes <i>DDX41</i>, <i>ETV6</i> and <i>GATA2</i> investigated in 1,228 Patients with Sporadic AML or MDS
Authors: Anna Maierhofer, Constance Baer, Christian Pohlkamp, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2020)
Vascular Events Amongst Patients with Sickle Cell Disease
Authors: Siddharth Bhesania, Nurunnisa Banu, Syed Adnan Ahmed Rafiuddin, Aisha Khader, Chadane Thompson, Sadaf Khan, Pritika Manaktala, Sahar Ilyas, Janki Bhesania, Achint Patel, Nivetha Vishnuvardhan, Parag Mehta, Eshan Patel
Journal: Blood (2020)
Bone Marrow Microenvironment Immune Cells Measured By Flow Cytometry Can Predict Survival and Identify a Subgroup in Risk of Early Relapse in Diffuse Large B Cell Lymphoma Patients
Authors: Laura Korin, Santiago Cranco, Maria Lucia Fuente, Paola Ochoa, Adriana Vitriu, Evelina Babuin, Maria Belen Venegas, Paula Tempra, Andrea Novoa, Anahí Vijnovich Baron, Fernando Diaz Couselo, Norma Elisabeth Tartas, Maria Del Rosario Custidiano, Maria Cecilia Foncuberta, Julio Cesar Sanchez Avalos
Journal: Blood (2020)
A Preliminary Assessment of Heterozygous<i>CFHR3-CFHR1</i>Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome
Authors: Andrew Jay Portuguese, Mark A Fiala, Tanya M. Wildes, Ravi Vij, Brea Lipe
Journal: Blood (2020)
Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS
Authors: Tracy Murphy, Brian Leber, Mark R Bray, Steven M Chan, Vikas Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Graham Fletcher, Debbie Valiquette, Kylie Martin, Mark D. Minden, Karen W.L. Yee
Journal: Blood (2020)
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome
Authors: Martí Duran-Ferrer, Guillem Clot, Ferran Nadeu, Renée Beekman, Tycho Baumann, Jessica Nordlund, Yanara Marincevic-Zuniga, Gudmar Lönnerholm, Alfredo Rivas-Delgado, Silvia Martín, Raquel Ordoñez, Giancarlo Castellano, Marta Kulis, Ana C. Queirós, Seung-Tae Lee, Joseph Wiemels, Romina Royo, Montserrat Puiggrós, Junyan Lu, Eva Giné, Sílvia Beà, Pedro Jares, Xabier Agirre, Felipe Prosper, Carlos López-Otín, Xosé S. Puente, Christopher C. Oakes, Thorsten Zenz, Julio Delgado, Armando López-Guillermo, Elías Campo, José Ignacio Martín-Subero
Journal: Nature Cancer (2020)
Trends in Appendicitis and Perforated Appendicitis Prevalence in Children in the United States, 2001-2015
Authors: Darryl T. Gray, Trina Mizrahi
Journal: JAMA Network Open (2020)

This sequential, cross-sectional study examines the prevalence of perforated appendicitis in children in the United States in relation to access to health care from 2001 to 2015.
Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
Authors: Sheeba K. Thomas, Jatin J. Shah, Armando Morin, Ashley N. Morphey, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Gregory P. Kaufman, Swami P. Iyer, Lei Feng, Behrang Amini, Muzaffar H. Qazilbash, Qaiser Bashir, Neeraj Saini, Samer A. Srour, Ralph J. Johnson, Brandon N. Crumpton, Mildred D. Stafford, Donna M. Weber, Robert Z. Orlowski
Journal: Blood (2020)
The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0
Authors: Andrey Garifullin, Sergei Voloshin, Sergey Linnikov, Irina Martynkevich, Alexey Kuvshinov, Anastasiya Kuzyaeva, Zhanna Chubukina, Vasily Shuvaev, Elizaveta Kleina, Marina Bakai, Alexander Sсhmidt
Journal: Blood (2020)
Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases
Authors: Maxime Jullien, Sylvie François, Ana Berceanu, Marie-Anne Couturier, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Marion Klemencie, Aline Schmidt, Mathilde Hunault, Etienne Daguindau, Eric Deconinck, Gaelle Guillerm, Aurelien Giltat, Corentin Orvain, Sylvain Thepot, Steven Le Gouill, Marie C Bene, Patrice Chevallier
Journal: Blood (2020)
A New Successful Rapid Desensitization Protocol for Hypersensitivity Reactions to Carboplatin and Rituximab in the Pediatric Setting
Authors: Faina Shenderov, Christopher Chang, Brian Cauff, Carmen Ballestas, Anne M Schaefer, Deborah Kramer, Kerice Pinkney, Ashley Siryk, Becky O'Neill, Melissa H Diaz, Iftikhar Hanif
Journal: Blood (2020)
Primary healthcare expansion and mortality in Brazil’s urban poor: A cohort analysis of 1.2 million adults
Authors: Thomas Hone, Valeria Saraceni, Claudia Medina Coeli, Anete Trajman, Davide Rasella, Christopher Millett, Betina Durovni
Journal: PLoS Medicine (2020)

Background Expanding delivery of primary healthcare to urban poor populations is a priority in many low- and middle-income countries. This remains a key challenge in Brazil despite expansion of the country's internationally recognized Family Health Strategy (FHS) over the past two decades. This study evaluates the impact of an ambitious program to rapidly expand FHS coverage in the city of Rio de Janeiro, Brazil, since 2008. Methods and findings A cohort of 1,241,351 low-income adults (observed January 2010–December 2016; total person-years 6,498,607) with linked FHS utilization and mortality records was analyzed using flexible parametric survival models. Time-to-death from all-causes and selected causes were estimated for FHS users and nonusers. Models employed inverse probability treatment weighting and regression adjustment (IPTW-RA). The cohort was 61% female (751,895) and had a mean age of 36 years (standard deviation 16.4). Only 18,721 individuals (1.5%) had higher education, whereas 102,899 (8%) had no formal education. Two thirds of individuals (827,250; 67%) were in receipt of conditional cash transfers (Bolsa Família). A total of 34,091 deaths were analyzed, of which 8,765 (26%) were due to cardiovascular disease; 5,777 (17%) were due to neoplasms; 5,683 (17%) were due to external causes; 3,152 (9%) were due to respiratory diseases; and 3,115 (9%) were due to infectious and parasitic diseases. One third of the cohort (467,155; 37.6%) used FHS services. In IPTW-RA survival analysis, an average FHS user had a 44% lower hazard of all-cause mortality (HR: 0.56, 95% CI 0.54–0.59, p < 0.001) and a 5-year risk reduction of 8.3 per 1,000 (95% CI 7.8–8.9, p < 0.001) compared with a non-FHS user. There were greater reductions in the risk of death for FHS users who were black (HR 0.50, 95% CI 0.46–0.54, p < 0.001) or pardo (HR 0.57, 95% CI 0.54–0.60, p < 0.001) compared with white (HR 0.59, 95% CI 0.56–0.63, p < 0.001); had lower educational attainment (HR 0.50, 95% CI 0.46–0.55, p < 0.001) for those with no education compared to no significant association for those with higher education (p = 0.758); or were in receipt of conditional cash transfers (Bolsa Família) (HR 0.51, 95% CI 0.49–0.54, p < 0.001) compared with nonrecipients (HR 0.63, 95% CI 0.60–0.67, p < 0.001). Key limitations in this study are potential unobserved confounding through selection into the program and linkage errors, although analytical approaches have minimized the potential for bias. Conclusions FHS utilization in urban poor populations in Brazil was associated with a lower risk of death, with greater reductions among more deprived race/ethnic and socioeconomic groups. Increased investment in primary healthcare is likely to improve health and reduce health inequalities in urban poor populations globally.
Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
Authors: Yuqin Song, Jun Zhu, Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Haijin Meng
Journal: Blood (2020)